AurÃ©lien Latouche

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2020806/publications.pdf

Version: 2024-02-01

46 papers	2,165 citations	279798 23 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	3996 citing authors

#	Article	IF	Citations
1	A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. Journal of Clinical Epidemiology, 2013, 66, 648-653.	5.0	339
2	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	6.3	206
3	Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood, 2002, 100, 3908-3918.	1.4	184
4	Simulating competing risks data in survival analysis. Statistics in Medicine, 2009, 28, 956-971.	1.6	151
5	Relative Index of Inequality and Slope Index of Inequality. Epidemiology, 2015, 26, 518-527.	2.7	149
6	Competing risks regression for clustered data. Biostatistics, 2012, 13, 371-383.	1.5	106
7	Sample size formula for proportional hazards modelling of competing risks. Statistics in Medicine, 2004, 23, 3263-3274.	1.6	84
8	Competing Risks Regression for Stratified Data. Biometrics, 2011, 67, 661-670.	1.4	78
9	Predictiveness curves in virtual screening. Journal of Cheminformatics, 2015, 7, 52.	6.1	73
10	Competing Events Influence Estimated Survival Probability. Clinical Orthopaedics and Related Research, 2007, 462, 229-233.	1.5	71
11	A review of the use of timeâ€varying covariates in the Fineâ€Gray subdistribution hazard competing risk regression model. Statistics in Medicine, 2020, 39, 103-113.	1.6	70
12	Misspecified regression model for the subdistribution hazard of a competing risk. Statistics in Medicine, 2007, 26, 965-974.	1.6	65
13	Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz026.	2.9	63
14	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials. JCO Precision Oncology, 2019, 3, 1-10.	3.0	51
15	Homebound status increases death risk within two years in the elderly: Results from a national longitudinal survey. Archives of Gerontology and Geriatrics, 2013, 56, 258-264.	3.0	41
16	Mortality in Female and Male French Olympians. American Journal of Sports Medicine, 2015, 43, 1505-1512.	4.2	38
17	Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clinical Cancer Research, 2021, 27, 5869-5877.	7.0	36
18	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine, 2003, 72, 117-125.	4.7	34

#	Article	IF	Citations
19	Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. Aids, 2009, 23, 377-383.	2.2	33
20	The heart of the matter: years-saved from cardiovascular and cancer deaths in an elite athlete cohort with over a century of follow-up. European Journal of Epidemiology, 2018, 33, 531-543.	5.7	32
21	A competing risks approach for nonparametric estimation of transition probabilities in a non-Markov illness-death model. Lifetime Data Analysis, 2014, 20, 495-513.	0.9	30
22	Learning From Leaders: Life-span Trends in Olympians and Supercentenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 944-949.	3.6	27
23	Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemporary Clinical Trials, 2008, 29, 220-230.	1.8	25
24	ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials. Computers in Biology and Medicine, 2019, 111, 103339.	7.0	22
25	Comments on â€˜Analysing and interpreting competing risk dataâ€™ by M. Pintilie,Statistics in Medicine 2006. DOI: 10.1002/sim.2655. Statistics in Medicine, 2007, 26, 3676-3679.	1.6	20
26	Regression modeling of the cumulative incidence function with missing causes of failure using pseudoâ€values. Statistics in Medicine, 2013, 32, 3206-3223.	1.6	18
27	Discrimination measures for survival outcomes: Connection between the AUC and the predictiveness curve. Biometrical Journal, 2011, 53, 217-236.	1.0	15
28	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3560-3570.	6.4	14
29	Access to Heart Transplantation: A Proper Analysis of the Competing Risks of Death and Transplantation Is Required to Optimize Graft Allocation. Transplantation Direct, 2017, 3, e198.	1.6	12
30	Time-Dependent AUC with Right-Censored Data: A Survey. Lecture Notes in Statistics, 2013, , 239-251.	0.2	12
31	Robustness of the BYM model in absence of spatial variation in the residuals. International Journal of Health Geographics, 2007, 6, 39.	2.5	11
32	Socioprofessional trajectories and mortality in France, 1976â€“2002: a longitudinal follow-up of administrative data. Journal of Epidemiology and Community Health, 2015, 69, 339-346.	3.7	11
33	Genetic markers and phosphoprotein forms of beta-catenin pÎ²-Cat552 and pÎ²-Cat675 are prognostic biomarkers of cervical cancer. EBioMedicine, 2020, 61, 103049.	6.1	10
34	Modeling timeâ€varying exposure using inverse probability of treatment weights. Biometrical Journal, 2018, 60, 323-332.	1.0	9
35	Direct Likelihood Inference and Sensitivity Analysis for Competing Risks Regression with Missing Causes of Failure. Biometrics, 2015, 71, 498-507.	1.4	8
36	A Regression Model for the Conditional Probability of a Competing Event: Application to Monoclonal Gammopathy of Unknown Significance. Journal of the Royal Statistical Society Series C: Applied Statistics, 2011, 60, 135-142.	1.0	7

#	Article	IF	Citations
37	A Note on the Measurement of Socioeconomic Inequalities in Life Years Lost by Cause of Death. Epidemiology, 2019, 30, 569-572.	2.7	3
38	Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile Regression. JCO Precision Oncology, 2021, 5, 173-176.	3.0	2
39	A Joint modelling of socio-professional trajectories and cause-specific mortality. Computational Statistics and Data Analysis, 2018, 119, 39-54.	1.2	1
40	Metaâ€analysis of clinical trials with competing timeâ€toâ€event endpoints. Biometrical Journal, 2020, 62, 712-723.	1.0	1
41	Authors' response. Statistics in Medicine, 2020, 39, 2692-2692.	1.6	1
42	A covariateâ€specific timeâ€dependent receiver operating characteristic curve for correlated survival data. Statistics in Medicine, 2020, 39, 2477-2489.	1.6	1
43	A parametric approach to relaxing the independence assumption in relative survival analysis. International Journal of Biostatistics, 2022, 18, 577-592.	0.7	1
44	Testing independence between two sequential gap times in the presence of covariates. Biometrical Journal, 2012, 54, 766-785.	1.0	0
45	On evaluating how well a biomarker can predict treatment response with survival data. Pharmaceutical Statistics, 2020, 19, 410-423.	1.3	0
46	Fermatâ€™s Passage. Epidemiology, 2020, 31, e47-e47.	2.7	0